QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
August 15 2022 - 3:05PM
Business Wire
- QIAstat-Dx Viral Vesicular Panel tests for six pathogens
that produce similar symptoms
- Panel boosts global research and surveillance of monkeypox
using gold-standard PCR technology
- QIAGEN offers broad testing portfolio to support healthcare
authorities around the globe, as it did with SARS-CoV-2
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced the launch of the QIAstat-Dx Viral Vesicular Panel RUO,
the first syndromic test to differentiate between monkeypox and
five other pathogens which cause similar symptoms.
The new panel – currently for research use only (RUO) – comes
in cartridge form to run on QIAGEN’s QIAstat-Dx automated syndromic
testing devices. It tests for the two known forms of monkeypox
virus (the so-called West African and Congo Basin clades), herpes
simplex virus 1 (HSV1), HSV2, human herpesvirus 6 (HH6),
varicella-zoster virus (VZV) and enterovirus – pathogens that all
produce similar-looking vesicular lesions.
With some 3,000 QIAstat-Dx PCR devices installed in specialized
laboratories around the world, QIAGEN is leveraging the value of
syndromic testing proven during the pandemic to help fight the
spread of monkeypox, recently declared a public health emergency by
the World Health Organization (WHO) and the US government.
“Monkeypox cases are soaring across the globe with many
demographic groups infected. Surveillance is an essential tool in
the fight against infectious diseases. QIAstat-Dx Viral Vesicular
Panel in combination with the QIAstat-Dx platform will allow
medical researchers to detect monkeypox with gold-standard PCR
testing-technology in about one hour,” said Jean-Pascal Viola,
Senior Vice President, Head of the Molecular Diagnostics Business
Area at QIAGEN. “Currently the world’s only syndromic test for the
pathogen, the panel will prove to be crucial for detecting and then
combatting the spread of monkeypox around the globe.”
The panel’s RUO-status means it currently can only be used for
the surveillance – not screening or diagnosing – of monkeypox
cases. But QIAGEN is ready to make applications for clinical use
should authorities in the United States and the European Union open
new diagnostic pathways in light of this public-health
emergency.
QIAGEN teams around the world are working with healthcare
authorities to support testing for the monkeypox virus outbreak.
The QIAstat syndromic testing solution adds to the broad portfolio
that the company offers to address all testing needs. Alongside
QIAGEN sample-technology kits, testing components and instruments
that are used for instance by public health agencies for the
development of their own tests, the NeuMoDx clinical PCR system
allows laboratories to process self-developed tests (LDTs). A
commercial single-plex assay running on this instrument is
currently in development. The QIAcuity digital PCR also allows for
monkeypox detection in wastewater – a surveillance method that
proved its worth during the COVID-19 crisis.
The concept of syndromic testing has shown its value during the
pandemic, when QIAGEN launched the QIAstat-Dx Respiratory
SARS-CoV-2 panel to differentiate between up to 23 viral and
bacterial targets for common pathogens causing respiratory tract
infections. The company also introduced the high-throughput
QIAstat-Dx Rise device that processes up 160 tests per day. QIAGEN
has extended syndromic testing to other areas, including
gastrointestinal conditions and meningitis.
To learn more about the QIAstat-Dx Viral Vesicular Panel and the
QIAstat-Dx range, please visit:
https://www.qiagen.com/applications/syndromic-testing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare) and
Life Sciences (academia, pharma R&D and industrial
applications, primarily forensics). As of June 30, 2022, QIAGEN
employed more than 6,100 people in over 35 locations worldwide.
Further information can be found at http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Source: QIAGEN N.V. Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220815005598/en/
Contacts QIAGEN:
Investor Relations John Gilardi +49 2103 29 11711 Phoebe
Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
e-mail: pr@QIAGEN.com
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (TG:QIA)
Historical Stock Chart
From Jul 2023 to Jul 2024